Profile data is unavailable for this security.
About the company
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
- Revenue in USD (TTM)0.00
- Net income in USD-2.54m
- Incorporated2021
- Employees8.00
- LocationCERo Therapeutics Holdings Inc201 Haskins Way, Suite 230SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (215) 731-9450
- Fax+1 (302) 636-5454
- Websitehttps://www.phoenixbiotechacquisitioncorp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weed Inc | 0.00 | 57.30k | 5.31m | 2.00 | 84.31 | 706.08 | 61.40 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Burzynski Research Institute Inc | 0.00 | -1.42m | 5.40m | 2.00 | -- | -- | -- | -- | -0.0108 | -0.0108 | 0.00 | -0.001 | 0.00 | -- | -- | -- | -153,444.30 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.30m | 5.53m | 4.00 | -- | 1.76 | -- | -- | -0.2603 | -0.2603 | 0.00 | 0.113 | 0.00 | -- | -- | 0.00 | -119.71 | -79.80 | -135.31 | -89.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.76 | -- | -- | -- |
| ELEVAI Labs Inc | 2.47m | -4.75m | 5.65m | 18.00 | -- | 2.00 | -- | 2.29 | -0.2698 | -0.2698 | 0.1408 | 0.1397 | 0.7249 | 1.04 | 95.33 | 137,407.20 | -139.23 | -- | -285.65 | -- | 69.25 | -- | -192.08 | -- | 0.5439 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| Marizyme Inc | 364.96k | -52.51m | 5.65m | 11.00 | -- | -- | -- | 15.49 | -0.974 | -0.974 | 0.004 | -0.0712 | 0.0125 | 1.31 | 10.00 | 33,178.18 | -179.49 | -59.02 | -742.64 | -64.47 | 70.17 | 70.38 | -14,389.19 | -9,435.92 | 0.038 | -0.6989 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -5.88m | 6.02m | 3.00 | -- | 0.4203 | -- | -- | -24.68 | -24.68 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -44.20 | -45.06 | -52.67 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -17.91m | 6.06m | 10.00 | -- | 1.93 | -- | -- | -75.48 | -75.48 | 0.00 | 0.182 | 0.00 | -- | -- | 0.00 | -334.48 | -133.14 | -973.00 | -181.26 | -- | -- | -- | -- | -- | -90.11 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 6.11m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.52m | -4.70m | 6.12m | 4.00 | -- | 0.8219 | -- | 2.43 | -3.05 | -3.05 | 1.64 | 4.83 | 0.2314 | -- | -- | 630,087.50 | -43.12 | -48.91 | -48.61 | -52.82 | -- | -- | -186.33 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Alzamend Neuro Inc | 0.00 | -7.39m | 6.57m | 4.00 | -- | -- | -- | -- | -10.69 | -10.69 | 0.00 | -1.41 | 0.00 | -- | -- | 0.00 | -344.10 | -177.86 | -- | -257.81 | -- | -- | -- | -- | -- | -363.62 | -- | -- | -- | -- | 33.14 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 6.70m | 7.00 | -- | 2.12 | -- | 171.28 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -12.19m | 6.72m | 4.00 | -- | 1.05 | -- | -- | -5.26 | -5.30 | 0.00 | 0.9961 | 0.00 | -- | -- | 0.00 | -279.27 | -182.35 | -320.96 | -235.45 | -- | -- | -- | -- | -- | -14.25 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -25.17m | 6.74m | 18.00 | -- | 0.3428 | -- | -- | -11.62 | -11.62 | 0.00 | 6.91 | 0.00 | -- | -- | 0.00 | -69.24 | -46.84 | -83.35 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Eterna Therapeutics Inc | 162.00k | -23.94m | 6.93m | 8.00 | -- | -- | -- | 42.75 | -4.42 | -4.42 | 0.0299 | -1.58 | 0.0035 | -- | 0.2673 | 20,250.00 | -51.20 | -169.05 | -62.39 | -223.00 | -111.11 | -- | -14,765.43 | -682.61 | -- | -10.12 | 10.22 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
Data as of Sep 23 2024. Currency figures normalised to CERo Therapeutics Holdings Inc's reporting currency: US Dollar USD
0.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Arena Investors LPas of 30 Jun 2024 | 198.57k | 0.39% |
| Avantax Planning Partners, Inc.as of 30 Jun 2024 | 80.00k | 0.16% |
| Fifth Lane Capital LPas of 30 Jun 2024 | 76.59k | 0.15% |
| Geode Capital Management LLCas of 30 Jun 2024 | 48.14k | 0.09% |
| Jane Street Capital LLCas of 30 Jun 2024 | 32.04k | 0.06% |
| Two Sigma Investments LPas of 30 Jun 2024 | 18.10k | 0.04% |
| Corient Private Wealth LLCas of 30 Jun 2024 | 15.00k | 0.03% |
| Birchview Capital LPas of 30 Jun 2024 | 12.97k | 0.03% |
| HRT Financial LLCas of 30 Jun 2024 | 11.94k | 0.02% |
| FNY Capital Management LPas of 30 Jun 2024 | 5.25k | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
